WASHINGTON: A single dose of Johnson & Johnson’s Covid-19 vaccine has been released in the U.S. Has been approved in This is the third vaccine in the US, after Pfizer and Mordana, that the FDA has approved for emergency use. FDA scientists have confirmed that the vaccine is about 66 percent effective in preventing moderate to severe levels of Covid-19 infection. It is 85 percent effective in very serious illness.
The Johnson & Johnson vaccine is safe to use, the FDA said. Only one dose will be needed instead of two from this vaccine. The company told the US Congress that it could supply 20 million doses by the end of March and 100 million doses by June. The company aims to produce one billion doses by the end of the year.
A single dose vaccine trial on 44,000 adults
Johnson & Johnson has tested its single-dose vaccine with two months of medical care for approximately 44,000 adults in the U.S., Latin America and South Africa. U.S. The FDA said of the vaccine: “This analysis meets all safety standards and does not identify any safety concerns that could impede its emergency use.”
U.S. In, the death toll from Covid-19 has reached about 1.5 lakh. However, the country is witnessing a gradual decline in infection rates. So far, the U.S. In about 45.5 million people have received at least one dose of a vaccine produced by Pfizer or Moderna. At the same time, 20 million people have received a second dose.